Psilocybin and Psychedelics: Texas Pushes for Access

Psilocybin FDA approval: Psilocybin and Psychedelics: Texas Pushes for Access

Federal momentum around psychedelic-assisted therapy accelerated in April 2026, when President Trump signed an executive order supporting state access programs, and the FDA announced fast-track vouchers for two psilocybin compounds and one MDMA-related drug. These are policy and regulatory developments, not yet approved treatments. Key takeaways FDA fast-track status is not approval. Three psychedelic compounds […]

Psilocybin for Trauma: What Early Research Shows

Psilocybin for Trauma: What Early Research Shows

A Psychology Today blog post surveys nascent clinical research suggesting that psilocybin, ketamine, and MDMA, each working through distinct brain mechanisms, may support trauma processing when paired with structured psychotherapy. The piece is commentary on early-stage evidence, not a primary study, and no firm conclusions can be drawn about efficacy or safety. Key takeaways Three […]

Psilocybin for Veterans: Bill Proposes $30M in Federal Funding

Psilocybin therapy for veterans: Saving Lives': Bill Would Fund Psychedelic Therapies for Military Veterans - Military.com

The Innovative Therapies Centers of Excellence Act of 2025, a bipartisan Senate bill, would allocate $30 million per year to fund at least five VA medical facilities offering research and treatment using psilocybin, MDMA, ibogaine, and DMT for veterans. The bill has not yet passed into law. Key takeaways Bipartisan momentum: The bill is co-sponsored […]

Psilocybin for Depression: What the Research Actually Shows

What to know about psychedelics treating mental health disorders amid Trump's executive order - ABC News - Breaking News, Latest News and Videos

In a 24-person Johns Hopkins study, antidepressant effects from psilocybin combined with supportive psychotherapy lasted at least a year in some patients with moderate to severe major depressive disorder. A separate small 2025 trial found similar durability in veterans, though most effects began to fade after nine months. Both are early, small studies. Key takeaways […]

Psilocybin for Veterans’ PTSD: Majority Reach Remission

Psilocybin therapy for veterans PTSD: Psilocybin for Veterans' PTSD: Majority Reach Remission

A clinical study examined psilocybin-assisted therapy in veterans diagnosed with PTSD and found that the majority of participants reached symptom remission. The findings are early-stage and require replication, but they add to a growing body of research suggesting psilocybin may merit serious attention for this high-need population. Key takeaways Remission in a majority of participants: […]

Psilocybin for Mental Health: Pa. Legislature Weighs Access

Pennsylvania psilocybin therapy bill: Psilocybin for Mental Health: Pa. Legislature Weighs Access

In September 2025, Pennsylvania House Democrats convened a policy committee hearing on a bipartisan bill that would legalize psilocybin therapy in the state, but only after federal FDA approval and DEA rescheduling. Veterans, attorneys, physicians, and biotech representatives all testified, reflecting broad interest in the proposal. Key takeaways A bipartisan bill is in play. State […]

Psilocybin for PTSD: Trials, Laws, and Early Evidence

Psilocybin for PTSD: Trials, Laws, and Early Evidence

In January 2026, the FDA accepted Compass Pathways’ Investigational New Drug Application to study its synthetic psilocybin compound, COMP360, as a possible therapy for PTSD. A separate randomized controlled trial at Johns Hopkins has also recently completed. Both are early-stage investigations, and no treatment has been approved. Key takeaways A late-stage trial is now authorized. […]

Senate Bill S.4031: Federal Psychedelic Research at the VA

Senate Bill S.4031 psychedelic research: Senate Bill S.4031: Federal Psychedelic Research at the VA

Senate Bill S.4031, the Innovative Therapies Centers of Excellence Act, would authorize the Department of Veterans Affairs to establish specialized centers studying psilocybin, MDMA, ibogaine, ketamine, and 5-MeO-DMT for conditions including PTSD and depression. The bill has been introduced but has not yet passed into law. Key takeaways A federal framework, not access: S.4031 does […]

Psilocybin for Veteran PTSD: Early Trial Remission Rates

Psilocybin for veteran PTSD: Psilocybin for Veteran PTSD: Early Trial Remission Rates

A clinical trial examined psilocybin-assisted therapy in veterans diagnosed with PTSD and reported striking remission rates among participants. This is early-phase human research, and the full details of sample size, controls, and duration have not been independently verified from the primary study text. Key takeaways Early human evidence: The trial involved veterans with PTSD, a […]

VA and HHS Sign Psychedelic Therapy Partnership for Veterans

VA psychedelic therapy veterans: VA and HHS Sign Psychedelic Therapy Partnership for Veterans

The Department of Veterans Affairs and the Department of Health and Human Services signed a memorandum of understanding in July 2026 to expand psychedelic therapy research and ready the VA for potential use of FDA-approved treatments. The partnership targets veterans with serious mental illness, a population HHS Secretary Kennedy estimated at roughly one million people. […]